These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39396349)

  • 1. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Qadri F; Khanam F; Zhang Y; Biswas PK; Voysey M; Mujadidi YF; Kelly S; Bhuiyan AI; Rajib NH; Hossen I; Rahman N; Islam S; Pitzer VE; Kim YC; Clemens JD; Pollard AJ; Liu X
    Lancet; 2024 Oct; 404(10461):1419-1429. PubMed ID: 39396349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
    Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    Lancet Glob Health; 2021 Nov; 9(11):e1561-e1568. PubMed ID: 34678198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
    Theiss-Nyland K; Qadri F; Colin-Jones R; Zaman K; Khanam F; Liu X; Voysey M; Khan A; Hasan N; Ashher F; Farooq YG; Pollard AJ; Clemens JD
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S74-S82. PubMed ID: 30845333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Patel PD; Liang Y; Meiring JE; Chasweka N; Patel P; Misiri T; Mwakiseghile F; Wachepa R; Banda HC; Shumba F; Kawalazira G; Dube Q; Nampota-Nkomba N; Nyirenda OM; Girmay T; Datta S; Jamka LP; Tracy JK; Laurens MB; Heyderman RS; Neuzil KM; Gordon MA;
    Lancet; 2024 Feb; 403(10425):459-468. PubMed ID: 38281499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
    Meiring JE; Laurens MB; Patel P; Patel P; Misiri T; Simiyu K; Mwakiseghile F; Tracy JK; Masesa C; Liang Y; Henrion M; Rotrosen E; Gmeiner M; Heyderman R; Kotloff K; Gordon MA; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S50-S58. PubMed ID: 30845320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
    Shakya M; Colin-Jones R; Theiss-Nyland K; Voysey M; Pant D; Smith N; Liu X; Tonks S; Mazur O; Farooq YG; Clarke J; Hill J; Adhikari A; Dongol S; Karkey A; Bajracharya B; Kelly S; Gurung M; Baker S; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
    N Engl J Med; 2019 Dec; 381(23):2209-2218. PubMed ID: 31800986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
    Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for preventing typhoid fever.
    Milligan R; Paul M; Richardson M; Neuberger A
    Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan.
    Qamar FN; Qureshi S; Haq Z; Yousafzai T; Qazi I; Irfan S; Iqbal N; Amalik Z; Hotwani A; Ali Q; Fatima I; Rahman N; Carter AS; Seidman JC
    Int J Infect Dis; 2024 Oct; 147():107187. PubMed ID: 39038733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
    Theiss-Nyland K; Shakya M; Colin-Jones R; Voysey M; Smith N; Karkey A; Dongol S; Pant D; Farooq YG; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S67-S73. PubMed ID: 30845329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.
    Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
    Vadrevu KM; Raju D; Rani S; Reddy S; Sarangi V; Ella R; Javvaji B; Mahantshetty NS; Battu S; Levine MM
    Vaccine; 2021 Oct; 39(45):6682-6690. PubMed ID: 34625288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
    Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
    Voysey M; Pollard AJ
    Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
    N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh.
    Tadesse BT; Khanam F; Ahmmed F; Im J; Islam MT; Kim DR; Kang SSY; Liu X; Chowdhury F; Ahmed T; Binte Aziz A; Hoque M; Park J; Pak G; Zaman K; Khan AI; Pollard AJ; Kim JH; Marks F; Qadri F; Clemens JD
    Clin Infect Dis; 2022 Nov; 75(10):1681-1687. PubMed ID: 35412603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.